1. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome;Alsaab;Front Pharm.,2017
2. Differential characteristics and prognosis of PD-L1-positive endometrial carcinomas: a retrospective chart review;Amarin;Life (Basel, Switz. ),2021
3. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial;Antill;J. Immunother. Cancer,2021
4. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019
5. Cai H. Correlation between HPV-specific immune response, PD-1/PD-L1 expression, clinical prognosis, and molecular characteristics in cervical squamous cell [PhD]: Xinjiang Medical University; 2021.